6 results about "Aspartate protease" patented technology

Present disclosure relates to a fusion protein, and a preparation method therefor and the use thereof. The fusion protein comprises a GSDME mutant protein and a tumor cell-specific cell-penetrating peptide. In the GSDME mutant protein, a tumor-targeting effect is provided by mutating a sequence recognized by cysteine-aspartic proteases in GSDME protein into an amino acid sequence recognized by matrix metalloproteinase; and the in-vitro misfolding rate of GSDME protein is reduced by means of mutating cysteine to alanine, increasing the druggability of the protein. The fusion protein which has a tumor targeting property, penetrating property and tumor microenvironment-specific activation is constructed, which provides a new idea for the development of targeted anti-cancer drug.

Provided herein are, inter alia, protease-activatable cytokines, as well as uses and methods of treatment. In particular, protease-activatable IL-12 fusion proteins, where the two subunits p40 and p35 are produced as fusion proteins with at least one masking moiety (Mask) linked to the subunit by a release segment (RS), namely, a cleavable linker, especially (i) not cleavable by legumain in human plasma, (ii) cleaved less than 25% compared to EAGRSANHTPAGLTGP (RSR-2295; SEQ ID NO:7048, legumain target) or, (iii) where the release segment comprises EAGRSAXHTPAGLTGP, X is any amino acid other than N (SEQ ID NO:7627). In preferred embodiments, each of the IL-12p35 and IL-12p40 subunits are linked at the N-and C-terminal ends by release segments (cleavable linker) to different masking moieties (Masks). In some embodiments, the fusion proteins further comprise barcodes.

The present application relates to a kind of preparation method of immunoglobulin powder and its application, the preparation method includes the following steps: collecting bovine colostrum, using cell survival technology is frozen;Frozen bovine colostrum is thawed, carries out milk fat separation, and obtains defatted bovine colostrum;Defatted bovine colostrum and composite rennet are mixed and are curdled, and then broken, obtain whey;The composite rennet includes aspartic protease, papain and bromelain;Whey is ultrafiltrated, and immunoglobulin solution is obtained;Immunoglobulin solution is vacuum freeze-dried, and the immunoglobulin powder is obtained.The preparation method provided by the present application is low temperature all the way, the activity of immunoglobulin is retained to the greatest extent, the use of composite rennet solves the problem of curd failure, and each link cooperates to improve the curd effect, realizes the preparation of high-efficiency, high-purity and high-quality immunoglobulin powder.

This disclosure relates to a drug delivery system comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, a tumor necrosis factor-α (TNF-α) or TNF receptor (TNFR) inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease (caspase) inhibitor, including any combination of these compounds and, optionally, a sustained delivery component. This type of drug delivery system can be used to treat a medical condition such as an inherited or age-related choroid, retina, optic nerve disorder, or optic nerve degeneration; an otic disorder; a neurologic or CNS disorder; or a related condition; or a condition related to occlusion or obstruction of a blood vessel or blood circulation such as a stroke, myocardial or renal infarction. Medicaments, methods of manufacturing medicaments, kits, and other related products or methods are also described.

The disclosure relates to methods for enhancing production of a heterologous protein in a plant or plant cell by inhibiting aspartic protease AED3-1. Also provided are plants and plant cells with enhanced production of a heterologous protein, wherein the plant or plant cell has reduced or loss of function of AED3-1. Further provided are shRNAs and vectors for use in enhancing production of a heterologous protein in a plant or plant cell.

The application discloses application of 1-aminocyclopropane carboxylic acid in preparation of a melanoma treatment drug and relates to the field of medicinal chemistry. The 1-aminocyclopropane carboxylic acid of the application effectively slows down melanoma cell proliferation by activating a cysteine aspartate protease cascade signal pathway, inhibiting extracellular regulatory protein kinase 1 / 2, phosphorylated protein kinase B and B lymphocyte tumor-2 signal pathways, and significantly reducing tumor tissue volume and mass, thereby playing an obvious curative effect.